Pfizer’s Tukysa added to maintenance therapy significantly delayed disease progression in patients with HER2-positive ...

Pfizer said on Tuesday it entered into an exclusive licensing agreement with YaoPharma, a subsidiary of China's Shanghai ...

China approves 19 innovative drugs for commercial health insurance, opening new market opportunities for global and local ...

Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. Keep ...

Its shares have declined by 50% over this period. But Pfizer's path to a rebound (unlike Teladoc's) seems clear. Even aside ...

Explore Alnylam Pharmaceuticals' outlook as TTR franchise growth, competitive pressures, and valuation create a potential ...

Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, ...

Pfizer is set to cut several jobs in Switzerland as part of a multi-year effort to lower expenses, as reported by Bloomberg.

After beefing up the target of its global cost-savings drive once again, Pfizer is continuing to see its plan through with ...

Pfizer is in the midst of an aggressive, multi-year cost-cutting effort, which so far has left nearly 2,000 people jobless.

Between heading to the Super Bowl and spending time with Taylor Swift, Travis Kelce is everywhere. Maybe that's why his ...

The latest trading day saw Pfizer (PFE) settling at $25.78, representing a +1.78% change from its previous close.